Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeStance Health GroupLFST +1.64%54 EV-to-Revenue is 3.14 as of Aug. 14, 2026, which is 17% above its 10-year median of 2.69. GuruFocus rates LFST with a GF Score™ of 54/100 and a GF Value™ of $8.53 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 665 Healthcare Providers & Services companies, LifeStance Health Group ranks worse than 68.87% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, LifeStance Health Group's enterprise value is $4,979 Mil.
LifeStance Health Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $1,585 Mil. Therefore, LifeStance Health Group's EV-to-Revenue for today is 3.14.
The historical rank and industry rank for LifeStance Health Group's EV-to-Revenue or its related term are showing as below:
LFST'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.32 Med: 2.69 Max: 26.54
Current: 3.14
During the past 7 years, the highest EV-to-Revenue of LifeStance Health Group was 26.54. The lowest was 1.32. And the median was 2.69.
LFST's EV-to-Revenue is ranked worse than 68.87% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 1.81
vs LFST: 3.14
LifeStance Health Group's share price for today is $12.42.
LifeStance Health Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeStance Health Group EV-to-Revenue Related Terms
LifeStance Health Group EV-to-Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, LifeStance Health Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeStance Health Group EV-to-Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LifeStance Health Group's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where LifeStance Health Group's EV-to-Revenue falls into.
LifeStance Health Group's current Enterprise Value is $4,979 Mil.
LifeStance Health Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,585 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeStance Health Group (LFST) has a EV-to-Revenue of 3.14 as of Aug. 14, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on LifeStance Health Group and its competitors. This is 17% above median its historical median of 2.69. Over the past decade, LifeStance Health Group's EV-to-Revenue has ranged from 1.32 to 26.54. According to the industry distribution chart, LifeStance Health Group ranks #458 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 68.9%.
Is LifeStance Health Group's EV-to-Revenue too high?
LifeStance Health Group's current EV-to-Revenue of 3.14 is 17% above median its 10-year median of 2.69. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 26.54. The Healthcare Providers & Services industry median EV-to-Revenue is 1.81. LifeStance Health Group's value of 3.14 is 73.5% above this industry median. Based on the distribution chart, LifeStance Health Group ranks #458 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, LifeStance Health Group has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's EV-to-Revenue compare to CON and BKD?
According to the Healthcare Providers & Services industry distribution chart, LifeStance Health Group ranks #458 out of 665 companies for EV-to-Revenue. This places LifeStance Health Group in the lower half of its industry. The industry median EV-to-Revenue is 1.81. LifeStance Health Group's value of 3.14 is 73.5% above this benchmark. Historically, LifeStance Health Group's own EV-to-Revenue has ranged from 1.32 to 26.54 over the past decade. While the company's 10-year median is 2.69 vs. the industry median of 1.81, LifeStance Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Healthcare Providers & Services company?
The median EV-to-Revenue among Healthcare Providers & Services companies is 1.81, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeStance Health Group's current EV-to-Revenue of 3.14 is 73.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on LifeStance Health Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-Revenue is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeStance Health Group's current EV-to-Revenue is 3.14, which is 17% above median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.53, compared to a current price of $12.42 — trading 45.6% above its estimated fair value. The current EV-to-Revenue is 3.14, which is 17% above median its 10-year median of 2.69 and 73.5% above the Healthcare Providers & Services industry median of 1.81. LifeStance Health Group's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current EV-to-Revenue is 3.14 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeStance Health Group (LFST) Overvalued in 2026?
Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued.
The current stock price of $12.42 is trading 45.6% above its estimated GF Value™ of $8.53.
GuruFocus considers LifeStance Health Group to be Significantly Overvalued.
Key valuation signals for LFST:
EV-to-Revenue: 3.14 (17% above median its 10-year median of 2.69)
GF Value™: $8.53 vs. price of $12.42 (45.6% above fair value)
Industry Position: 73.5% above the Healthcare Providers & Services median (#458 of 665)
No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
54GF Score
Get the complete analysis for LFST
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFST has been successfully added to your 
